SCHEMBL9325925

SCHEMBL9325925

Cc1cc(C(=O)c2ccccc2)ccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 1/20 0.57
ATM Q13315 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SRD5A2 P31213 2/20 0.55
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
HTT P42858 1/20 0.50
NPC1 O15118 3/20 0.49
POLB P06746 2/20 0.49
MITF O75030 1/20 0.49
LMNA P02545 1/20 0.49
S1PR3 Q99500 1/20 0.48
RAB9A P51151 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HPGD P15428 2/20 0.47
PBRM1 Q86U86 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4352652 0.90 HTT (0.53) VCAM1TDP1SRD5A2ALDH1A1SMN1; SMN2
SCHEMBL22193831 0.86 PARP1 (0.50) VCAM1SRD5A2ALDH1A1SMN1; SMN2HTT
SCHEMBL13176761 0.85 ATM (0.55) VCAM1ATMTDP1L3MBTL1SRD5A2
SCHEMBL333237 0.82 SRD5A2 (0.78) VCAM1ATMTDP1L3MBTL1SRD5A2
SCHEMBL10007010 0.82 SMN1; SMN2 (0.71) ATMTDP1L3MBTL1SRD5A2ALDH1A1
SCHEMBL166495 0.82 SMN1; SMN2 (0.71) ATMTDP1L3MBTL1SRD5A2ALDH1A1
SCHEMBL27893118 0.81 ALDH1A1 (0.56) ATMTDP1L3MBTL1SRD5A2ALDH1A1
SCHEMBL12337417 0.81 ALDH1A1 (0.61) ATMTDP1L3MBTL1SRD5A2ALDH1A1
SCHEMBL703101 0.80 TSHR (0.65) TDP1L3MBTL1SRD5A2ALDH1A1SMN1; SMN2
SCHEMBL13236538 0.79 TDP1 (0.69) ATMTDP1L3MBTL1SRD5A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230225991-A1 COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA VESTLANDETS INNOVASJONSSELSKAP AS (NO) 2023-07-20 US disclosed
CN-105418393-B Two step one-pot synthesis methods of meta position substituted benzophenone class compound 陕西师范大学 2018-07-10 CN disclosed
CN-105418393-A Two-step one-pot synthesis method for meta-substituted diphenyl ketone compound UNIV SHAANXI NORMAL 2016-03-23 CN disclosed
EP-0268112-B1 A novel aromatic polyether and a process for producing a polyether ASAHI CHEMICAL IND (JP) 1994-03-16 EP disclosed
US-4931530-A Novel aromatic polyether and a process for producing an ether ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1990-06-05 US disclosed
EP-0268112-A2 A novel aromatic polyether and a process for producing a polyether Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1988-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230225991-A1 COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA HMBS, POR, CYP2A13 VCAM1 4637/4885ATM 3906/4885TDP1 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.